Likitocin Allegheny Health Network (AHN) sun shiga wani gwaji na asibiti mai ban mamaki da ke binciko aminci da ingancin aikin haɓakar ƙwaƙwalwa mai zurfi don magance cutar Alzheimer. Jagoran Donald Whiting, MD, shugaban AHN's Neurosciences Institute, Babban Jami'in Kiwon Lafiya na AHN, kuma majagaba a cikin amfani da DBS don magance nau'o'in nau'in cututtuka masu lalacewa, Nazarin ADvance II shine gwajin gwaji na asibiti na duniya na 3 wanda ake ba da shi kawai. a zaɓaɓɓun cibiyoyin kiwon lafiya a duk duniya.
eTurboNews labarai na masu biyan kuɗi ne kawai. Biyan kuɗi shine FREE.
Masu biyan kuɗi suna shiga nan Danna nan don biyan kuɗi FREE
Masu biyan kuɗi suna shiga nan Danna nan don biyan kuɗi FREE
ABUBUWAN DA ZA KU GUDU DAGA WANNAN LABARI:
- Led by Donald Whiting, MD, chair of AHN’s Neurosciences Institute, Chief Medical Officer for AHN, and a pioneer in the use of DBS to treat a variety of debilitating neurological conditions, the ADvance II Study is an international phase 3 clinical trial being offered only at select medical centers world-wide.
- Allegheny Health Network (AHN) physicians have joined a landmark clinical trial exploring the safety and efficacy of deep brain stimulation therapy to treat Alzheimer’s disease.
- eTurboNews labarai na masu biyan kuɗi ne kawai.
